EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis

Sudheer K Vuyyuru, Nader Shaban, Yuhong Yuan, Sailish Honap, Lotus Alphonsus, Theshani Amalka De Silva, Abdulaziz Alajmi, John K MacDonald, Christopher Ma, Parambir S Dulai, Laurent Peyrin Biroulet, Vipul Jairath

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2025.03.007 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Sudheer K Vuyyuru und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Alimentiv, Inc, London, Ontario, Canada. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Gastrointestinal Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Acute severe ulcerative colitis (ASUC) is a medical emergency associated with high morbidity and mortality. We aimed to assess the efficacy and safety of medical treatments for ASUC. METHODS: MEDLINE, EMBASE, and CENTRAL were searched to November 14, 2024 for randomized controlled trials (placebo or active comparator), and comparative cohort studies that evaluated medical therapies for hospitalized adults with ASUC. Primary outcomes were colectomy rate at discharge and at 3 and 12 months. Safety outcomes included adverse events, serious adverse events, and infections. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated. RESULTS: Forty-four studies (18 randomized controlled trials, and 26 cohort studies) assessing 22 different comparisons were included. Low certainty evidence suggests that infliximab (IFX) was significantly superior to cyclosporine A for reducing the risk of colectomy at discharge (RR, 0.56; 95% CI, 0.38-0.81; I2 = 30%), 3 months (RR, 0.67; 95% CI, 0.48-0.92; I2 = 36%), and 12 months (RR, 0.56; 95% CI, 0.42-0.75; I2 = 46%). IFX patients were significantly more likely than cyclosporine A patients to develop an infection (RR, 2.38; 95% CI, 1.27-4.47; I2 = 15%). There was no significant difference between accelerated and standard dosing regimens of IFX for colectomy at discharge or at 3 months. Tofacitinib in combination with intravenous corticosteroids was significantly superior to intravenous corticosteroids alone for induction of clinical response at Day 7; however, there was no difference in colectomy rate or infections at 3 months. CONCLUSIONS: IFX may be more efficacious than cyclosporine A for the treatment of ASUC. Janus kinase inhibitors are promising treatment options in select individuals. Future studies should explore the efficacy of other advanced therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeGastrointestinal AgentsHumansInfliximabColectomyRandomized Controlled Trials as TopicCyclosporineAcute DiseaseTreatment OutcomePyrimidinesPiperidinesImmunosuppressive AgentsAdult

Stichwörter der Autor:innen

BiologicsInfliximabSmall MoleculesUlcerative Colitis

Substanzen

InfliximabCyclosporinetofacitinibGastrointestinal AgentsPyrimidinesPiperidinesImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Alimentiv, Inc, London, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada.
  • School of Immunology & Microbial Sciences, King's College London, London, United Kingdom; INFINY Institute, Nancy University Hospital Center, Vandœuvre-lès-Nancy, France.
  • Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
  • Alimentiv, Inc, London, Ontario, Canada.

Zitieren

APA

Vuyyuru, S. K., Shaban, N., Yuan, Y., Honap, S., Alphonsus, L., De Silva, T. A., Alajmi, A., MacDonald, J. K., Ma, C., Dulai, P. S., Peyrin Biroulet, L., & Jairath, V. (2025). Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2025.03.007

Vancouver

Vuyyuru SK, Shaban N, Yuan Y, Honap S, Alphonsus L, De Silva TA, et al. Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2025.03.007

BibTeX
@article{Vuyyuru2025,
  author = {Vuyyuru, Sudheer K and Shaban, Nader and Yuan, Yuhong and Honap, Sailish and Alphonsus, Lotus and De Silva, Theshani Amalka and Alajmi, Abdulaziz and MacDonald, John K and Ma, Christopher and Dulai, Parambir S and Peyrin Biroulet, Laurent and Jairath, Vipul},
  title = {Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2025.03.007}
}
Kostenlos starten →